From health to stealth - management of hospitalized patients on SGLT2 inhibitors

Presenter: Tanya O'Brien, BSc. Pharm

Learning Objectives:

1. Describe the mechanism of action of Sodium-glucose transport protein 2 (SGLT2) inhibitors.
2. State the evidence for SGLT2 inhibitors in Cardiovascular (CV) patients.
3. Identify the pathophysiology of euglycemic diabetic ketoacidosis (DKA) with SGLT2 inhibitors.
4. Apply various health agency's recommendations for SGLT2 inhibitors to patients in the hospital setting.
5. Illustrate some cases of eDKA at Eastern Health and apply various health agency's recommendations for SGLT2 inhibitors in the hospital setting.
6. Summarize appropriate management of hospitalized patients on SGLT2 inhibitors

Register here